Emergency Awards: Exosome-based Non-traditional Technologies Towards Multi-Parametric and Integrated Approaches for SARS-CoV-2 (U18 Clinical Trial Not Allowed)

0
219

Funding Opportunity ID:328568
Opportunity Number:RFA-OD-20-018
Opportunity Title:Emergency Awards: Exosome-based Non-traditional Technologies Towards Multi-Parametric and Integrated Approaches for SARS-CoV-2 (U18 Clinical Trial Not Allowed)
Opportunity Category:Discretionary
Opportunity Category Explanation:
Funding Instrument Type:Cooperative Agreement
Category of Funding Activity:Education
Health
Category Explanation:
CFDA Number(s):93.073
93.233
93.279
93.310
93.350
93.394
93.837
93.838
93.839
93.840
93.866
Eligible Applicants:State governments
County governments
City or township governments
Special district governments
Independent school districts
Public and State controlled institutions of higher education
Native American tribal governments (Federally recognized)
Public housing authorities/Indian housing authorities
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
For profit organizations other than small businesses
Small businesses
Others (see text field entitled “Additional Information on Eligibility” for clarification)
Additional Information on Eligibility:Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Agency Code:HHS-NIH11
Agency Name:Department of Health and Human Services
National Institutes of Health
Posted Date:Aug 06, 2020
Close Date:Sep 18, 2020
Last Updated Date:Aug 06, 2020
Award Ceiling:$0
Award Floor:$0
Estimated Total Program Funding:$10,000,000
Expected Number of Awards:5
Description:In response to the declared public health emergency issued by the Secretary, Department of Health and Human Services (DHHS) for the 2019 Novel Coronavirus (COVID-19), the National Institutes of Health (NIH) has launched the Rapid Acceleration of Diagnostics (RADx) project. This emergency funding opportunity announcement (FOA) from NIH provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative for the development of novel, non-traditional approaches to identify the current SARS-CoV-2 virus or other markers of the COVID-19 disease that can be used in future outbreaks of COVID-19 and that could be applicable to other, as yet unknown, viruses. Specifically, this FOA seeks to use developed technologies for single vesicle or exosome isolation and analysis and reposition these technologies for the detection of SARS-CoV-2. The funding for this initiative is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020. NIH requires that all projects funded under this FOA will actively coordinate, collaborate, and share data with the RADx-rad Data Coordinating Center, as allowed, and with considerations under tribal IRB processes, as appropriate. Researchers applying to this funding opportunity are strongly encouraged to review the companion Data Coordinating Center (DCC) funding opportunity announcement.
Version:1





Visit the Official Webpage For More Details on Emergency Awards: Exosome-based Non-traditional Technologies Towards Multi-Parametric and Integrated Approaches for SARS-CoV-2 (U18 Clinical Trial Not Allowed)

LEAVE A REPLY

Please enter your comment!
Please enter your name here